Journal
PEPTIDES
Volume 30, Issue 7, Pages 1276-1281Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2009.04.004
Keywords
MIF-1; Peptide; Brain; Peptidases; Mass spectrometry; Multiple reaction monitoring (MRM)
Funding
- NINDS NIH HHS [R01 NS062291] Funding Source: Medline
Ask authors/readers for more resources
MIF-1 (Pro-Leu-Gly-NH2) has potent therapeutic effects in depression and Parkinson's disease, but its CNS sites of production are not yet clear. In this study, the concentration of MIF-1 in different brain regions was measured by the multiple reaction monitoring technique on a 4000 QTRAP mass spectrometer. The limit of quantification was 300 fg of MIF-1, and limit of detection was 60 fg. The low molecular weight fractions of tissue homogenates from different regions of mouse brain were analyzed. The concentration of MIF-1 ranged from 22 +/- 3 fg/mu g protein in cerebral cortex to 930 +/- 60 fg/mu g protein in the hypothalamus. Moderate concentrations were also detected in all other regions tested, including the striatum, thalamus, and hippocampus. By incubation of stable isotope-labeled oxytocin with tissue preparations, it was also confirmed that oxytocin at least partially contributed to the production of MIF-1 in the hypothalamus by action of peptidases. Regional differences were also found. The results are the first to show the ultrasensitive quantification of MIF-1 in different brain regions, and support the neuromodulatory actions of MIF-1 in the striatum. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available